MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes-Reference-Cited by-同舟云学术

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes

Published:2023-09 Issue:6 Volume:24 Page:483-497
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Mazieres Julien^ORCID,Vioix Helene,Pfeiffer Boris M.,Campden Rhiannon I.,Chen Zhiyuan,Heeg Bart,Cortot Alexis B.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference89 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version 5.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (2022).

3. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations;Paik;N Engl J Med,2020

4. Capmatinib in MET exon 14–mutated or MET -amplified non–small-cell lung cancer;Wolf;N Engl J Med,2020

5. Characterization of non-small-cell lung cancers with MET exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns;Lee;JCO Precis Oncol,2021

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology;Lung Cancer;2024-10

2. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study;Lung Cancer;2024-10

3. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study;The Lancet Respiratory Medicine;2024-09

4. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis;BMC Cancer;2024-07-15

5. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a MET exon 14 mutation;Personalized Medicine;2024-07-03